Skip to main content

Oyler John's Form 4 filing

BeOne Medicines Ltd. (ONC) · filed Jun 15, 2026

Accession no.
0001042047-26-000005
Filed
Jun 15, 2026
Trade date
Jun 11, 2026
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $501.4K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Oyler JohnCIK 0001042047Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 11, 2026Ordinary SharesAGrant or awardAcquired+177,931$0.00$05,697,649Direct
Jun 11, 2026American Depositary SharesSSaleDisposed−741$256.23F9−$189,866.431,208Direct
Jun 11, 2026American Depositary SharesSSaleDisposed−859$257.59F10−$221,269.81349Direct
Jun 11, 2026American Depositary SharesSSaleDisposed−200$258.28F11−$51,656149Direct
Jun 11, 2026American Depositary SharesSSaleDisposed−149$258.81−$38,562.690Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 11, 2026Ordinary SharesAGrant or awardAcquired+344,669$0.00$0344,669Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $256.04 to $257.00, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $257.105 to $257.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F11

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $258.1269 to $258.3723, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)